Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes” (original) (raw)

Articles

Letter to the Editor

Clinical and Molecular Hepatology 2023;29(3):810-811.
Published online: May 8, 2023

1Department of Biomedical Informatics, CHA University School of Medicine, CHA University, Seongnam, Korea

2Institute of Biomedical Informatics, CHA University School of Medicine, CHA University, Seongnam, Korea

Corresponding author : Hyun Wook Han Department of Biomedical Informatics, CHA University School of Medicine, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam 13488, Korea Tel: +82-31-881-7109, Fax: +82-31-881-7069, E-mail: stepano7@gmail.com

• Received: March 29, 2023 • Revised: April 5, 2023 • Accepted: April 5, 2023

Copyright © 2023 by The Korean Association for the Study of the Liver

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Full Article

Dear Editor,

We read with great interest the study by Han et al. [1], which reviewed the basic definition of non-alcoholic fatty liver disease (NAFLD) and its subtypes, including non-alcoholic fatty liver (NAFL), NAFL with inflammation, and non-alcoholic steatohepatitis (NASH). Conventional classification of NAFLD subtypes, classification by severity, and classification using scoring systems, such as the NAFLD activity score or fibrosis score, have provided an in-depth understanding of the disease status and the risk of liver cirrhosis and hepatocellular carcinoma [2,3]. However, none of the classifications targeted the risk of cardiovascular disease (CVD) and dementia according to NAFLD status.

In recent years, NAFLD has been found to increase the risk of several extrahepatic diseases, including CVD and dementia [4,5]. Previously, we used the Korean National Health and Nutrition Examination Survey-derived NAFLD (K-NAFLD) score, which was externally validated in an independent population using FibroScan, to evaluate the risk of CVD. We found that low-intermediate and high hepatic steatosis were associated with 30% and 55% higher risk of CVD, respectively [6,7]. Furthermore, high steatosis with at least two forms of metabolic dysfunction was associated with a 71% higher risk of CVD compared to high steatosis without metabolic dysfunction. Therefore, the use of the K-NAFLD score, along with metabolic dysfunction, may be useful in classifying NAFLD in terms of CVD risk.

NAFLD has also been found to be a risk factor for the development of dementia [5,8]. After independent propensity score matching between the low-intermediate and intermediatehigh fatty liver index (FLI) groups, we found a 4% lower and 5% higher risk of dementia for the low FLI group (FLI<30) and high FLI group (FLI≥60), respectively, compared with the intermediate FLI group (FLI≥30 and <60). Additionally, in a preclinical study, NAFLD-induced chronic hepatic inflammation was associated with the pathogenesis of Alzheimer’s disease through the induction of neurodegeneration [9]. Lipocalin-2, an adipokine that is exclusively produced in NASH liver and circulates in the bloodstream, has also been found to activate pro-inflammatory processes and weaken the blood-brain barrier [10,11]. Therefore, the severity of steatosis and the presence of NASH may be useful in classifying patients who are at higher NAFLD-associated risk of dementia.

Taken together, clinicians need to consider NAFLD-associated non-liver comorbidities as an important aspect of the management and classification of the disease [12]. The use of NAFLD scoring systems, metabolic dysfunction, and the severity of steatosis or the presence of NASH may provide insight into the development of NAFLD subtypes in terms of CVD and dementia risk.

FOOTNOTES

Authors’ contribution

Conception or design of the work: Seogsong Jeong. Drafting the article: Seogsong Jeong. Critical revision of the article: All authors. Final approval of the version to be published: All authors.

Conflicts of Interest

The authors have no conflicts to disclose.

Abbreviations

NAFLD

non-alcoholic fatty liver disease

NAFL

non-alcoholic fatty liver

NASH

non-alcoholic steatohepatitis

K-NAFLD

Korean National Health and Nutrition Examination Survey-derived NAFLD

REFERENCES

Figure & Data

References

Citations

Citations to this article as recorded by Crossref logo

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

Include:

Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”

Clin Mol Hepatol. 2023;29(3):810-811. Published online May 8, 2023

Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”

Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”